Publicaciones en colaboración con investigadores/as de Universidad de Sevilla (14)

2022

  1. Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease

    Clinical Parkinsonism and Related Disorders, Vol. 7

2018

  1. Oleoylethanolamide and Palmitoylethanolamide Protect Cultured Cortical Neurons Against Hypoxia

    Cannabis and Cannabinoid Research, Vol. 3, Núm. 1, pp. 171-178

2014

  1. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism

    International Journal of Neuropsychopharmacology, Vol. 17, Núm. 3, pp. 455-468

2013

  1. Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism

    Addiction Biology, Vol. 18, Núm. 1, pp. 78-87

2010

  1. Effects of the endogenous PPAR-α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice

    Synapse, Vol. 64, Núm. 5, pp. 379-389

2009

  1. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons

    Neuropharmacology, Vol. 56, Núm. 3, pp. 653-664

  2. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells

    Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1791, Núm. 8, pp. 740-745

  3. Role of cannabis and endocannabinoids in the genesis of schizophrenia

    Psychopharmacology, Vol. 206, Núm. 4, pp. 531-549

  4. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine

    Neuroscience, Vol. 164, Núm. 2, pp. 667-675

2008

  1. Expression and function of CB1 receptor in the rat striatum: Localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors

    Neuropsychopharmacology, Vol. 33, Núm. 7, pp. 1667-1679

2007

  1. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies

    European Journal of Pharmacology, Vol. 559, Núm. 2-3, pp. 180-183

2005

  1. Acute Δ9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion

    Pharmacology Biochemistry and Behavior, Vol. 81, Núm. 1, pp. 71-77

  2. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

    Neurobiology of Disease, Vol. 18, Núm. 3, pp. 591-601

2004

  1. Experimental Parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: A modulator of endocannabinoid function

    Neuropsychopharmacology, Vol. 29, Núm. 6, pp. 1134-1142